Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.74 |
| ▸ | HTT | P42858 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | GCGR | P47871 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12387970 | 0.86 | KDM4E (0.72) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL12388069 | 0.84 | MAPT (0.67) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL12387732 | 0.82 | MAPT (0.75) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL12388087 | 0.82 | NPC1 (0.70) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL684611 | 0.81 | MEN1 (0.71) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL1638694 | 0.81 | HTT (0.64) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL1638697 | 0.81 | HTT (0.64) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL12387784 | 0.80 | NPC1 (0.60) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL12387900 | 0.79 | KDM4E (0.70) | KDM4EKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL12387764 | 0.79 | MAPT (0.73) | KDM4EKMT2AHTTMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189306-A1 | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES | KARTNER NORBERT | 2011-08-04 | — | — | US | disclosed |
| US-20110189306-A1 | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES | KARTNER NORBERT | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189306-A1 | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES | ATP6V1E1, ATP6V1G1, ATP6V1H | KDM4E 2907/4885KMT2A 2682/4885HTT 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.